Signal transduction

US Radiology Specialists Selects Fujifilm’s Synapse Enterprise Information System to Drive Efficiency and Improve Patient Experience Across its Network

Retrieved on: 
Monday, July 26, 2021
Radiological information system, Radiology, Signal transduction, Synapse, Fujifilm, Branches of biology, Optics, Industry economics)

Synapse EIS, based on the foundation of Fujifilms Synapse Radiology Information System (RIS), is a comprehensive workflow management solution designed to streamline physician communication, improve patient interaction, and alleviate administrative burden for the outpatient imaging market.

Key Points: 
  • Synapse EIS, based on the foundation of Fujifilms Synapse Radiology Information System (RIS), is a comprehensive workflow management solution designed to streamline physician communication, improve patient interaction, and alleviate administrative burden for the outpatient imaging market.
  • Synapse EIS exceeded our expectations in terms of scalability, efficiency, and customer ROI and we are excited to extend the Synapse solutions throughout our network.
  • Fujifilms Synapse RIS has been relied upon as the core information system at American Health Imaging and Touchstone Medical Imaging, both US Radiology partners, as those companies experienced exceptional rates of growth over the past 14 years.
  • Learn more about Fujifilms Synapse Enterprise Information System solutions by visiting SynapseEIS.com, and at HIMSS 2021 booth # 3837.

Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study

Retrieved on: 
Wednesday, July 14, 2021
Tyrosine kinases, Branches of biology, Signal transduction, Organ systems, Tyrosine kinase 2, Galapagos NV, Psoriasis, Tyrosine kinase, Biology, Janus kinase inhibitor, Janus kinase 3 inhibitor

Mechelen, Belgium; 14 July 2021; 22.01 CET; regulated information - Galapagos NV (Euronext & Nasdaq: GLPG) reports positive topline results with tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b study in psoriasis patients.

Key Points: 
  • Mechelen, Belgium; 14 July 2021; 22.01 CET; regulated information - Galapagos NV (Euronext & Nasdaq: GLPG) reports positive topline results with tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b study in psoriasis patients.
  • Galapagos evaluated GLPG3667, a proprietary selective TYK2 compound, in a randomized, placebo-controlled, double-blind Phase 1b study in 31 patients with diagnosis of moderate to severe plaque psoriasis.
  • Main objectives were to evaluate the safety and tolerability of GLPG3667 as well as signs of clinical activity at Week 4.
  • Based on these results, we aim to initiate a global Phase 2b program in psoriasis next year as part of a program to develop our selective oral TYK2 inhibitor GLPG3667 broadly in inflammatory indications.

Aadi Bioscience to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference

Retrieved on: 
Wednesday, July 7, 2021
Life sciences, Biology, Branches of biology, Signal transduction, Biotechnology, MTOR, Biopharmaceutical, Cancer

LOS ANGELES, July 07, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Aadi), a privately-held clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Tuesday, July 13, 2021.

Key Points: 
  • LOS ANGELES, July 07, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Aadi), a privately-held clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Tuesday, July 13, 2021.
  • A replay will also be available at this link and posted on Aadis website within the Investors & News/ Events & Presentations section.
  • Aadi is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers.
  • FYARRO is an investigational drug that has not been approved by the FDA for commercial distribution in the United States.

TYK2 Kinase Inhibitors Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 7, 2021
Health, Pharmaceutical, Signal transduction, Tyrosine kinases, Tyrosine kinase 2, Pipeline, Tyrosine kinase

The "TYK2 Kinase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "TYK2 Kinase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "TYK2 kinase inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in TYK2 kinase inhibitors pipeline landscape.
  • This segment of the report provides insights about the different TYK2 kinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • TYK2 kinase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Lysine Specific Demethylase 1 Inhibitors Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 6, 2021
Health, Pharmaceutical, Enzymes, Demethylase, Signal transduction, KDM7A, Histone demethylase

The "Lysine Specific Demethylase 1 Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Lysine Specific Demethylase 1 Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Lysine specific demethylase 1 inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 11+ companies and 11+ pipeline drugs in Lysine specific demethylase 1 inhibitors pipeline landscape.
  • Lysine specific demethylase 1 inhibitors: Therapeutic Assessment
    This segment of the report provides insights about the different Lysine specific demethylase 1 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Lysine specific demethylase 1 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene

Retrieved on: 
Wednesday, June 30, 2021
Oncology, Health, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Biology, Autophagy, Cell death, Immunology, Programmed cell death, Signal transduction, MEK inhibitor, MTOR, Ras GTPase

The ULK kinase initiates the autophagy pathway and provides a potential targeted approach to selectively inhibiting autophagy in cancers caused by RAS or RAF mutations.

Key Points: 
  • The ULK kinase initiates the autophagy pathway and provides a potential targeted approach to selectively inhibiting autophagy in cancers caused by RAS or RAF mutations.
  • In preclinical studies, DCC-3116 was observed to potently and durably inhibit autophagy in RAS and RAF mutant cancer cell lines through the inhibition of ULK kinase.
  • The Phase 1, multicenter, open-label, first-in-human study will evaluate DCC-3116 as a single agent and in combination with trametinib, an FDA-approved MEK inhibitor, in patients with advanced or metastatic tumors with a mutant RAS or RAF gene.
  • QINLOCK and the QINLOCK logo are registered trademarks, and Deciphera and the Deciphera logo are trademarks, of Deciphera Pharmaceuticals, LLC.

Angion Announces Results from the Phase 2 ALI-201 Study in Patients with COVID-19 Associated Pneumonia

Retrieved on: 
Tuesday, June 29, 2021
Branches of biology, Biology, MTOR, Signal transduction, Tyrosine kinase receptors, Lactams, Protein kinase inhibitors

The adverse events and overall safety of the trial were consistent with previously published reports in patients hospitalized with severe COVID-19 pneumonia.

Key Points: 
  • The adverse events and overall safety of the trial were consistent with previously published reports in patients hospitalized with severe COVID-19 pneumonia.
  • In contrast, patients in our ongoing trials receive ANG-3777 within 1-3 days after the targeted organ injury.
  • Angion is also currently evaluating ANG-3070, a tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in Phase 1.
  • Angion undertakes no obligation to update any forward-looking statement in this press release, except as required by law.

Surrozen Presents Data at 2021 International Liver Conference for Wnt-Modulating Antibody SZN-043

Retrieved on: 
Friday, June 25, 2021
Branches of biology, Biology, Signal transduction, Glycoproteins, Evolutionary developmental biology, Genes, Wnt signaling pathway, C-Met, Immunoglobulin G

The one oral presentation and three poster presentations discussed data from studies of SZN-043, Surrozens hepatocyte-targeted R-spondin mimetic, in mice and various disease models.

Key Points: 
  • The one oral presentation and three poster presentations discussed data from studies of SZN-043, Surrozens hepatocyte-targeted R-spondin mimetic, in mice and various disease models.
  • SZN-043 showed target-mediated drug disposition and pharmacokinetics that were consistent with that of an IgG-based molecule binding to the hepatocyte membrane protein ASGR1.
  • Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway.
  • Investors and security holders of Surrozen are advised to read, when available, the proxy statement/prospectus in connection with the written consent of Surrozen stockholders.

Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1

Retrieved on: 
Thursday, June 24, 2021
Branches of biology, Biology, Protein complexes, Signal transduction, mTORC1, G proteins, MTOR, Tumor suppressor gene, Ras GTPase, Cancer, mTOR inhibitors

Revolution Medicines recently advanced RMC-5552, the companys investigational first-in-class bi-steric mTORC1 inhibitor, into clinical development.

Key Points: 
  • Revolution Medicines recently advanced RMC-5552, the companys investigational first-in-class bi-steric mTORC1 inhibitor, into clinical development.
  • The compound is designed to inhibit mTORC1 and thereby protect the natural tumor suppressor activity of 4EBP1, without the undesirable inhibition of mTORC2.
  • Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers.
  • RAS(ON) Inhibitors in development include RMC-6291 and RMC-6236, and a pipeline of research compounds targeting additional RAS variants.

2021 Report on TGF Beta Receptor Type 2 Drugs in Development - Featuring Auxagen, InteRNA Technologies and Velvio Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 22, 2021
Health, Pharmaceutical, Branches of biology, Proteins, Biology, TGF beta receptors, Signal transduction, TGF beta receptor 2, Growth factors, Transforming growth factor beta, Transforming growth factor, TGF beta signaling pathway, TGF beta receptor 1

The "TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to this report TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) pipeline Target constitutes close to 7 molecules.
  • TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Transforming growth factor beta receptor II is a TGF beta receptor encoded by TGFBR2 gene.
  • It also reviews key players involved in TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics development with respective active and dormant or discontinued projects.